Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
We utilise our cutting-edge, exclusive workflow to develop focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.
Several key aspects differentiate our library:
partner
Reaxense
upacc
P16118
UPID:
F261_HUMAN
Alternative names:
6PF-2-K/Fru-2,6-P2ase liver isozyme
Alternative UPACC:
P16118; B2RA88; B4DUN5; Q5JXS5; Q99951
Background:
The 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 1, known as 6PF-2-K/Fru-2,6-P2ase liver isozyme, plays a pivotal role in the synthesis and degradation of fructose 2,6-bisphosphate. This enzyme is crucial for regulating glycolysis and gluconeogenesis, balancing energy production and glucose synthesis in the liver.
Therapeutic significance:
Understanding the role of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 1 could open doors to potential therapeutic strategies. Its central function in metabolic pathways highlights its potential as a target for treating metabolic disorders.